Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Choi

Showing results (21-30 of 46) with videos related to

Pageof 5
Sort By:
Vaccine|February 7, 2025
A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adultsMieke Soens, Jintanat Ananworanich, Bryony Hicks, et al.
Immunohorizons|April 30, 2019
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in MiceAngela Choi, Badiaa Bouzya, Klaus-Daniel Cortés Franco, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2021
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variantsKai Wu, Anne P Werner, Juan I Moliva, et al.
NPJ Vaccines|December 17, 2019
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohortsRaffael Nachbagauer, Bruno Salaun, Daniel Stadlbauer, et al.
Nature Medicine|September 16, 2021
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysisAngela Choi, Matthew Koch, Kai Wu, et al.
The Lancet. Infectious Diseases|September 8, 2024
Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50-75 years: a phase 1/2, open-label, randomised trialDenise Hsu, Akila Jayaraman, Alicia Pucci, et al.
Cell Host & Microbe|June 10, 2016
Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer ProtectionCarole J Henry Dunand, Paul E Leon, Min Huang, et al.
Biorxiv : the Preprint Server for Biology|October 27, 2020
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein VaccineSonia Jangra, Jana De Vrieze, Angela Choi, et al.
Angewandte Chemie (International Ed. in English)|January 19, 2021
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*Sonia Jangra, Jana De Vrieze, Angela Choi, et al.
Iscience|July 31, 2023
Spatiotemporally organized immunomodulatory response to SARS-CoV-2 virus in primary human broncho-alveolar epitheliaDiana Cadena Castaneda, Sonia Jangra, Marina Yurieva, et al.
Pageof 5

Showing results (21-30 of 46) with videos related to

Sort By:
Pageof 5
Vaccine|February 7, 2025
A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adultsMieke Soens, Jintanat Ananworanich, Bryony Hicks, et al.
Immunohorizons|April 30, 2019
Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in MiceAngela Choi, Badiaa Bouzya, Klaus-Daniel Cortés Franco, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2021
mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variantsKai Wu, Anne P Werner, Juan I Moliva, et al.
NPJ Vaccines|December 17, 2019
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohortsRaffael Nachbagauer, Bruno Salaun, Daniel Stadlbauer, et al.
Nature Medicine|September 16, 2021
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysisAngela Choi, Matthew Koch, Kai Wu, et al.
The Lancet. Infectious Diseases|September 8, 2024
Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50-75 years: a phase 1/2, open-label, randomised trialDenise Hsu, Akila Jayaraman, Alicia Pucci, et al.
Cell Host & Microbe|June 10, 2016
Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer ProtectionCarole J Henry Dunand, Paul E Leon, Min Huang, et al.
Biorxiv : the Preprint Server for Biology|October 27, 2020
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein VaccineSonia Jangra, Jana De Vrieze, Angela Choi, et al.
Angewandte Chemie (International Ed. in English)|January 19, 2021
Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*Sonia Jangra, Jana De Vrieze, Angela Choi, et al.
Iscience|July 31, 2023
Spatiotemporally organized immunomodulatory response to SARS-CoV-2 virus in primary human broncho-alveolar epitheliaDiana Cadena Castaneda, Sonia Jangra, Marina Yurieva, et al.
Pageof 5